The company said an antibody-based drug met the main goal of a mid-to-late stage trial testing it as a therapy to protect infants from disease caused by the respiratory syncytial virus.
Tag Archive for: Merck
The company has beaten back an appeal by nearly 1,200 plaintiffs who claimed their cases were improperly dismissed by the federal judge overseeing mass torts litigation over its Zostavax shingles vaccine.
The acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration, as well as preclinical candidates.
Unlike the current commercially available pneumococcal vaccines—including its top competitor, Pfizer’s Prevnar 20—Capvaxive covers eight unique serotypes that together account for around 27% of IPD cases in patients 50 years and older, and approximately 30% of cases in seniors 65 years and older.
The FDA rejected Merck and Daiichi Sankyo’s antibody-drug conjugate patritumab deruxtecan in a Complete Response Letter, citing problems with a third-party manufacturer.
Merck KGaA’s drug candidate xevinapant in a late-stage trial was unable to significantly improve event-free survival in patients with locally advanced head and neck cancer.
Merck is eyeing market opportunities with additional potential benefits of weight-loss treatments through drug combinations with “good tolerability and good combinability”.
While the science at ASCO continued to push the boundaries for cancer care, much of the conversation in the hallways revolved around the ever-increasing challenges on translating trial successes into clinical practice.
The companies announced today that their cancer vaccine in combination with blockbuster cancer therapy Keytruda improved survival and showed durable efficacy in a mid-stage study in patients with a deadly form of skin cancer.
Today the company announced a deal worth $3 billion to buy EyeBio and its first-in-class trispecific antibody Restoret, marking the pharma’s return to the ophthalmology space after nearly a decade.